All In Biotech

Drug Trial Radar · NCT03191799

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

195

Actual

Start

Sep 5, 2017

Primary completion

Nov 19, 2020

Study completion Nov 19, 2020

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.

Conditions

  • Hemophilia A

Interventions

  • EmicizumabDrug

    Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading ScaleTime frame: From Baseline until study completion (up to 2 years)
  2. Adverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEsTime frame: From Baseline until study completion (up to 2 years)
  3. Number of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-BaselineTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
  4. Change From Baseline in Body Temperature at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
  5. Change From Baseline in Systolic Blood Pressure at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
  6. Change From Baseline in Diastolic Blood Pressure at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
  7. Change From Baseline in Pulse Rate at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
  8. Change From Baseline in Respiratory Rate at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
  9. Change From Baseline in Body Weight at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)

Locations

72 sites in 24 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital; Haematology

    Camperdown, New South Wales, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Centro de Hematologia E Hemoterapia Do Parana - Hemepar

    Curitiba, Paraná, Brazil

  • Instituto Estadual de Hema

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital das Clinicas - UNICAMP

    Campinas, São Paulo, Brazil

  • Faculdade de Medicina de Ribeirão Preto - Universidade de Sao Paulo

    Ribeirão Preto, São Paulo, Brazil

  • Kaye Edmonton Clinic

    Edmonton, Alberta, Canada

  • CancerCare Manitoba; Neuro-Oncology

    Winnipeg, Manitoba, Canada

  • McMaster University Health Sciences Center

    Hamilton, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Centro de Atención e Investigación Médica CAIMED S.A.S

    Localidad Puente Aranda, Colombia

  • Hospital Pablo Tobon Uribe

    Medellín, Colombia

  • Helsingin yliopistollinen keskussairaala, Meilahden sairaala

    Helsinki, Finland

  • Vivantes Klinikum im Friedrichshain - Landsberger Allee, Angiologie und Hämostaseologie

    Berlin, Germany

  • Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin

    Bonn, Germany

  • Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin; Johann Wolfgang Goethe-Univers.

    Frankfurt/M., Germany

  • Universitätsklinikum Leipzig, Innere Medizin, Neurologie, Dermatologie; Zentrum für Hämostaseologie

    Leipzig, Germany

  • Hämophilie-Zentrum Rhein Main GmbH

    Mörfelden-Walldorf, Germany

  • Klinikum der Universität München, Campus Innenstadt; Hämostaseologische Ambulanz/Hämophiliezentrum

    München, Germany

  • Oncomedica

    Guatemala City, Guatemala

  • Magyar Honvédség Egészségügyi Központ; Országos Haemophilia Központ

    Budapest, Hungary

  • Országos Vérellátó Szolgálat - Győri Regionális Vérellátó Központ

    Győr, Hungary

  • University of Pecs, I st Dept of Internal Medicine

    Pécs, Hungary

  • Grant Medical Foundation, Ruby Hall Clinic

    Pune, India

  • St. John's Medical College & Hospital; Department of Medicine

    Bengaluru, Karnataka, India

  • King Edward Memorial Hospital and Seth G.S. Medical College; Department of Hematology

    Mumbai, Maharashtra, India

  • Fortis Hospitals Limited

    Mumbai, Maharashtra, India

  • Sahyadri Speciality Hospital; Hematology & Bone Marrow Unit

    Pune, Maharashtra, India

  • Christian Medical College & Hospital; Department of Haematology

    Vellore, Maharashtra, India

  • Nil Ratan Sircar Medical College and Hospital; Department of Hematology

    Kolkata, West Bengal, India

  • Sheba Medical Center - National Hemophilia Center

    Tel HaShomer, Israel

  • AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia

    Naples, Campania, Italy

  • AOU Policlinico S. Orsola Malpighi; U.O. Angiologia e Malattie della Coagulazione Marino Golinelli

    Bologna, Emilia-Romagna, Italy

  • AOU di Parma; Dip Emergenza-Urgenza Centro Riferimento Regionale per l'emofilia

    Parma, Emilia-Romagna, Italy

  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol

    Rome, Lazio, Italy

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"

    Milan, Lombardy, Italy

  • AO Città Salute e Scienza D-Osp S. G. Battista Molinette; SSCVD Malattie Tromboti e Emorragiche

    Turin, Piedmont, Italy

  • Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto

    Palermo, Sicily, Italy

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.